guidance.fyi
Company, ticker, metric, guidance, or anything said
Q2 FY27
13 Oct 2026
VerifiedNumbers checked and claims independently audited

Transcript ↗

Healthcare Global Enterprises LimitedPharmaceuticals & HealthcareHCG

Q2 FY27 concall · earnings callHealthcare Global Enterprises Limited

HCG has scheduled its Q2 FY27 earnings call for November 6, 2026 to discuss results to be declared on November 5, 2026, with no financials disclosed in this intimation.

Neutral tone2-minute briefPublished the same day as the call

Financials

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹557.55 Cr+18.7% YoY+0.7% QoQ₹7.75 Cr+125.9% YoY-62.5% QoQ₹0.50+22% YoY-61.2% QoQ
Q2 FY25₹553.54 Cr+13.7% YoY+5.3% QoQ₹20.68 Cr+91.8% YoY+51.7% QoQ₹1.29+31.6% YoY+48.3% QoQ
Q1 FY25₹525.58 Cr+14.1% YoY+6.3% QoQ₹13.63 Cr+273.4% YoY-41.9% QoQ₹0.87+58.2% YoY-43.1% QoQ
Q4 FY24₹494.63 Cr+12% YoY+5.3% QoQ₹23.46 Cr+315.2% YoY+584% QoQ₹1.53+155% YoY+273.2% QoQ
Q3 FY24₹469.87 Cr+10.6% YoY-3.5% QoQ₹3.43 Cr-18.3% YoY-68.2% QoQ₹0.41-24.1% YoY-58.2% QoQ
TL;DR
  • Earnings conference call scheduled for 12:30 pm IST on Friday, November 6, 2026 to discuss unaudited financial results for the quarter and six months ended September 30, 2026.
  • Board meeting to consider the results is scheduled for November 5, 2026; no results or financial numbers were disclosed in this intimation.
Source

Summary written from the transcript filed by Healthcare Global Enterprises Limited for the call held on 13 Oct 2026; published 13 Oct 2026, 19:34 IST.

More Q2 FY27 concalls ·How verification works ·Report an error

Same sector

Others in Pharmaceuticals & Healthcare

All Pharmaceuticals & Healthcare →
  • Granules India LimitedQ2 FY27Positive tone

    Management said Granules returned to growth in FY26 and is shifting from building manufacturing and R&D capabilities to scaling four growth engines of controlled substances, complex generics with first-to-file opportunities, oncology and peptide CDMO.

    Gross margin
    65 percentabout 15 percentage points
    EBITDA margin
    22 percentthree percentage points
    GRANULESPharmaceuticals & HealthcareVerified brief4 guidance items
  • Symbiotec Pharmalab LimitedQ1 FY27Positive tone

    Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.

    Consolidated revenue Q1 FY27
    ₹218 Crgrowth of 7% YoY
    API revenue Q1 FY27
    ₹215 Crgrowth of 6% YoY
    SYMBIOTECPharmaceuticals & HealthcareVerified brief6 guidance items
  • Molbio Diagnostics LimitedQ1 FY27Positive tone

    Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.

    Revenue from operations (Q1 FY27)
    ₹408 Cr
    EBITDA (Q1 FY27)
    ₹104 Cr
    MOLBIOPharmaceuticals & HealthcareVerified brief3 guidance items
  • Fischer Medical Ventures LtdQ1 FY27Neutral tone

    Fischer Medical Ventures used its September 7, 2026 investor call to present its AI-enabled imaging platform, proprietary technology stack and leadership team, without disclosing quarterly financial results.

    FISCHERPharmaceuticals & HealthcareVerified brief
  • Fortis Healthcare LimitedQ1 FY27Positive tone

    Delhi High Court ordered a court-supervised forensic audit into erstwhile promoter share dissipation, IHH's acquisition of control and use of funds for RHT assets, which Fortis and IHH say leaves operations, capex, bed expansion and M&A unrestricted and is expected to have no material adverse outcome.

    FORTISPharmaceuticals & HealthcareVerified brief4 guidance items